ZA200006947B - Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. - Google Patents

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.

Info

Publication number
ZA200006947B
ZA200006947B ZA200006947A ZA200006947A ZA200006947B ZA 200006947 B ZA200006947 B ZA 200006947B ZA 200006947 A ZA200006947 A ZA 200006947A ZA 200006947 A ZA200006947 A ZA 200006947A ZA 200006947 B ZA200006947 B ZA 200006947B
Authority
ZA
South Africa
Prior art keywords
carboxyamino
tetrahydroquinoline
substituted
making
Prior art date
Application number
ZA200006947A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200006947B publication Critical patent/ZA200006947B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200006947A 1999-11-30 2000-11-27 Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. ZA200006947B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ZA200006947B true ZA200006947B (en) 2002-05-27

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200006947A ZA200006947B (en) 1999-11-30 2000-11-27 Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.

Country Status (45)

Country Link
US (1) US6313142B1 (fr)
EP (1) EP1125929B1 (fr)
JP (1) JP3579345B2 (fr)
KR (1) KR100408177B1 (fr)
CN (1) CN1173953C (fr)
AP (1) AP2000002011A0 (fr)
AR (1) AR029775A1 (fr)
AT (1) ATE315028T1 (fr)
AU (1) AU784694B2 (fr)
BG (1) BG105009A (fr)
BR (1) BR0005636A (fr)
CA (1) CA2327029C (fr)
CO (1) CO5261552A1 (fr)
CY (1) CY1104989T1 (fr)
CZ (1) CZ20004407A3 (fr)
DE (1) DE60025317T2 (fr)
DK (1) DK1125929T3 (fr)
DZ (1) DZ3079A1 (fr)
EA (1) EA003668B1 (fr)
EE (1) EE200000659A (fr)
ES (1) ES2254109T3 (fr)
GE (1) GEP20022798B (fr)
GT (1) GT200000190A (fr)
HK (1) HK1038007A1 (fr)
HN (1) HN2000000203A (fr)
HR (1) HRP20000804A2 (fr)
HU (1) HUP0004747A3 (fr)
ID (1) ID28489A (fr)
IL (1) IL139849A (fr)
IS (1) IS5715A (fr)
MA (1) MA25223A1 (fr)
NO (1) NO20006039L (fr)
NZ (1) NZ508509A (fr)
OA (1) OA11494A (fr)
PA (1) PA8503801A1 (fr)
PE (1) PE20010913A1 (fr)
PL (1) PL344208A1 (fr)
SG (1) SG102603A1 (fr)
SK (1) SK17792000A3 (fr)
TN (1) TNSN00230A1 (fr)
TW (1) TW591016B (fr)
UA (1) UA65615C2 (fr)
UY (1) UY26451A1 (fr)
YU (1) YU71500A (fr)
ZA (1) ZA200006947B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
WO2003053359A2 (fr) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
AU2003230916A1 (en) * 2002-04-11 2003-10-27 Roar Holding Llc Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004078730A2 (fr) * 2003-03-04 2004-09-16 Takasago International Corporation Procede de production d'amines optiquement actives
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
ES2377121T3 (es) * 2003-03-17 2012-03-22 Japan Tobacco Inc. Composiciones farmacéuticas de inhibidores de CETP
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DK1670768T3 (da) * 2003-10-08 2009-11-09 Lilly Co Eli Forbindelser og fremgangsmåder til at behandle dyslipidæmi
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
WO2006069162A1 (fr) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (fr) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
OA11494A (en) 2004-05-07
SG102603A1 (en) 2004-03-26
NO20006039D0 (no) 2000-11-29
IS5715A (is) 2001-05-31
TW591016B (en) 2004-06-11
HU0004747D0 (fr) 2001-02-28
HUP0004747A2 (hu) 2001-10-28
KR100408177B1 (ko) 2003-12-01
AU784694B2 (en) 2006-06-01
US6313142B1 (en) 2001-11-06
BG105009A (en) 2001-11-30
TNSN00230A1 (fr) 2005-11-10
CO5261552A1 (es) 2003-03-31
AU7178900A (en) 2001-05-31
UA65615C2 (uk) 2004-04-15
EA200001129A3 (ru) 2001-10-22
HRP20000804A2 (en) 2001-06-30
CA2327029C (fr) 2005-08-09
PE20010913A1 (es) 2001-09-10
DZ3079A1 (fr) 2004-10-24
NZ508509A (en) 2001-06-29
DE60025317T2 (de) 2006-08-03
MA25223A1 (fr) 2001-07-02
EP1125929A1 (fr) 2001-08-22
IL139849A0 (en) 2002-02-10
EA200001129A2 (ru) 2001-06-25
EA003668B1 (ru) 2003-08-28
CY1104989T1 (el) 2010-03-03
ID28489A (id) 2001-05-31
GT200000190A (es) 2002-04-27
CZ20004407A3 (cs) 2002-06-12
KR20010052012A (ko) 2001-06-25
HN2000000203A (es) 2001-06-13
EP1125929B1 (fr) 2006-01-04
HK1038007A1 (en) 2002-03-01
ATE315028T1 (de) 2006-02-15
BR0005636A (pt) 2001-07-17
CN1302800A (zh) 2001-07-11
CA2327029A1 (fr) 2001-05-30
EE200000659A (et) 2001-08-15
CN1173953C (zh) 2004-11-03
SK17792000A3 (sk) 2002-10-08
GEP20022798B (en) 2002-09-25
HUP0004747A3 (en) 2002-12-28
IL139849A (en) 2006-10-31
ES2254109T3 (es) 2006-06-16
DK1125929T3 (da) 2006-04-03
UY26451A1 (es) 2001-06-29
AR029775A1 (es) 2003-07-16
AP2000002011A0 (en) 2000-12-31
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
DE60025317D1 (de) 2006-03-30
NO20006039L (no) 2001-05-31
YU71500A (sh) 2003-02-28
JP2001163859A (ja) 2001-06-19
PA8503801A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
HK1038007A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.
ZA200007593B (en) Quinoline Derivatives.
PL349504A1 (en) 1,2-annelated quinoline derivatives
AU5439899A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
PL348827A1 (en) Process for making 2,3-dihalopropanols
ZA200110096B (en) Method for making microabrasive tools.
ZA200001333B (en) Method for communicating information.
ZA200202843B (en) Method for improving growth.
HK1052702A1 (en) Method for the preparation of 5-carboxyphthalide.
ZA200105294B (en) Method for producing L-phenylephrine hydrochloride.
ZA200007253B (en) Process for preparing 1,4-dihydropyridine compounds.
ZA200003020B (en) Method for producing platinum.
HK1044780A1 (en) Method for producing cyclo-)asp-dphe-nmeval-arg-gly).
HK1030422A1 (en) Method for preparing oxazaphosphorin-2-amines.
IL146573A0 (en) Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones
HUP0302821A2 (hu) Eljárás szubsztituált 5-amino-N-fenil-1,2,4-triazol-3-szulfonamid-származékok előállítására
GB2353794B (en) Deadplate assembly for I.S. machine
GB9914600D0 (en) Novel,process
ZA200005740B (en) Improved method for preparing pharmaceutically valuable norbenzomorphane derivatives.
HK1031881A1 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-Äsu bstitutedÜ-5,8-dihydro-4H-1,2,3A, 7,8-pentaaza-as-indacenes and intermediates useful therein.
IL130732A0 (en) Method for making 1,2-dibromoindane
HUP0202890A3 (en) Method for preparing quinoline-5,8-diones
AU2001234795A1 (en) Process for obtaining 1, 2, 3, 5, 6, 7, 8, 8a-oltahydro-1, 2, 8, 8tetramethylnaphthalen-2-yl!etan-1-one
GC0000055A (en) Method for making dimethylnaphthalenes.
GB2358324B (en) Method for fast retrain for g.lite